What are the key risks and potential rewards of buying Pfizer stock for its 6.9% dividend yield?

Buying Pfizer stock for a roughly 6.9% dividend yield means weighing a stream of sizable quarterly payments against real concerns about whether that stream can last—and what might happen to the share price in the meantime. The latest data paints a mixed picture.

Potential Rewards

• High current income: The dividend is $0.43 per share each quarter, or $1.72 annually, which at recent prices gives a yield near 6.96% [1][2][4][7]. Management has publicly stated it intends to keep the dividend even while prioritizing drug development over buybacks [21].
• Underlying business growth: Excluding COVID‑related products and drugs losing exclusivity, Pfizer expects 4% operational revenue growth in 2026 [22]. The company also beat fourth‑quarter revenue and earnings estimates [23], showing that the core business is not falling apart.
• Cash generation: Free cash flow rebounded to $9.835 billion in 2024, more than doubling the prior year’s figure [5]. The company is also described as having stable margins and billions in cash flow [8].
• Pipeline and diversification: A diverse product portfolio, strong international sales [26], a potential new standard of care in prostate cancer [29], and an industry‑wide forecast of 20 or more billion‑dollar acquisitions in 2026 (with $1.2 trillion in deal capacity) [14] could help Pfizer fill revenue gaps left by expiring patents.
• Analyst support: The consensus rating on the stock is a Buy [30]. The highest 1‑year price target is $36, implying possible share price upside [34]; the lowest target of $24 sits close to current levels, suggesting limited downside risk according to those specific forecasts [35].

Key Risks

• Dividend sustainability in question: The dividend payout ratio is 131.30%, which “may not be sustainable” [3]. Meanwhile, the cost of sales as a percentage of revenue rose 3.8 percentage points in the first quarter of 2026 [16], squeezing the cash available for payouts. Concerns exist about Pfizer’s ability to maintain that payout ratio [25].
• COVID revenue decline and patent cliff: Pfizer expects a $1.5 billion drop in COVID product revenue in 2026 [15]. It also anticipates another $1.5 billion loss from exclusivity [15]. Specific hits include Eliquis (subject to Medicare price negotiation in 2026) [12] and Ibrance (patent expiry in 2027) [11]. Broader analyses project that Pfizer could see revenue drops of up to 62% by 2030 because of the patent cliff [10][13].
• Stock price damage: The shares have already lost more than 50% since 2023 [19] and fell 5% on the day the 2026 earnings guidance was released [18]. The average analyst price target of $29.50 implies no price appreciation from current levels [31], and one specific forecast for September 2026 sees the stock moving between $22.40 and $26.30 [32] — meaning potential capital loss.
• Cash flow volatility and pipeline gaps: Free cash flow collapsed from $29.9 billion in 2021 to $4.8 billion in 2023 before recovering [5][6], showing how quickly conditions can change. Pfizer’s pipeline is described as slow, with obesity drug candidates lagging behind competitors [27][28], which could limit its ability to replace aging blockbusters.

The 2026 revenue guidance of $59.5–$62.5 billion [17][33] already reflects many of these headwinds, so any additional revenue deterioration would put even more strain on the dividend.